載入中
NASDAQHealthcareBiotechnology
最新資料
US$12.7723
−US$0.1427 · -1.10%
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
一般交易時段
US$12.7723
−US$0.1427 · -1.10%
盤中時間採用ET。市場資料可能有所延遲。
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
日內區間
目前US$12.7723
52週區間
目前US$12.7723
盤中時間採用ET。市場資料可能有所延遲。
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
日內區間
目前US$12.7723
52週區間
目前US$12.7723
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.64億 USD | 1.64億 USD | 118.9萬 USD | — | — |
| 銷貨成本 | 728.6萬 USD | 1.24億 USD | 1075.5萬 USD | — | — |
| 毛利 | 2.56億 USD | 4007.5萬 USD | −956.6萬 USD | — | — |
| 研究與開發 | 3億 USD | 2.82億 USD | 3.44億 USD | 2.95億 USD | 2.59億 USD |
| 銷售、一般及管理費用 | 1.52億 USD | 1.53億 USD | 1.07億 USD | 1.04億 USD | 8366.4萬 USD |
| 營業費用 | 6.6億 USD | 4.35億 USD | 4.51億 USD | 3.99億 USD | 3.43億 USD |
| 利息收入 | — | 2027.3萬 USD | 1304.3萬 USD | 298.5萬 USD | 45.1萬 USD |
| 利息支出 | — | — | — | 298.5萬 USD | — |
| 折舊和攤銷 | 4732.4萬 USD | 4360.6萬 USD | 3312.7萬 USD | 2113.5萬 USD | 1398萬 USD |
| 營業利益 | −4.03億 USD | −3.95億 USD | −4.61億 USD | −3.99億 USD | −3.43億 USD |
| 淨利 | −3.91億 USD | −3.72億 USD | −4.44億 USD | −3.96億 USD | −3.42億 USD |
公司資料更新於 2026年10月8日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.53億1.48%100.75億 USD0.35%US$146.4-2.55%
iShares Russell 2000 ETFIWM1.35億0.17%785.63億 USD0.19%US$275.28-0.87%
Vanguard Morningstar Total Stock Market ETFVTI1.1億0.00%2.3兆 USD0.03%US$379.96-0.28%
Vanguard Morningstar Small-Cap ETFVB3984.98萬0.02%1853億 USD0.03%US$285.61-0.48%
iShares Biotechnology ETFIBB3843.57萬0.37%104.01億 USD0.44%US$197.28-2.98%
Vanguard Extended Market ETFVXF3564.41萬0.04%954億 USD0.05%US$231.94-0.66%
Dimensional - US Small Cap ETFDFAS2762.01萬0.08%336.6億 USD0.31%US$77.525-0.51%
Schwab U.S. Small-Cap ETFSCHA2662.12萬0.12%216.99億 USD0.03%US$32.375-0.72%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
